Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alexandre Lebeaut

- PMLiVE

Ipsen to acquire rare disease specialist Albireo in deal worth over $950m

The deal will strengthen the biopharma’s liver disease pipeline with the addition of Bylvay

- PMLiVE

Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma

The treatment showed a significant improvement in overall survival versus placebo

- PMLiVE

Ipsen’s Sohonos approved by Health Canada

The drug is the first approved treatment for individuals with fibrodysplasia ossificans progressiva

- PMLiVE

Revenue growth at Ipsen numbs pain of palovarotene calamity

French speciality drugmaker posted €2.58bn sales for the full-year

- PMLiVE

Ipsen buys rare disease group Clementia in $1.3bn deal

Will acquire lead multiple rare disease candidate palovarotene

- PMLiVE

Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

The latest industry movers

- PMLiVE

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

Drug increased PFS by 2.6 months compared to Pfizer’s Sutent

- PMLiVE

Ipsen bolsters leadership team

Ivana Magovcevic-Liebisch and Régis Mulot join the biopharma

- PMLiVE

Dr Sotirios Stergiopoulos leaves Shire for Ipsen

He becomes the French biopharma’s chief medical officer

- PMLiVE

Richard Paulson joins Ipsen as CEO for North America

He also becomes an executive vice-president at the French biopharma

- PMLiVE

Ipsen appoints Aidan Murphy as EVP, technical operations

He is promoted from senior VP biologics development and manufacturing

- PMLiVE

Accelerating innovation

Ipsen’s Alexandre Lebeaut on the French firm’s oncology plans, global focus and R&D approach

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links